About Us
MAP/PATH L.L.C. is an early-stage company that in 2022 began work on a patented, rapid, lateral flow assay TB test. It has unique features that we believe will displace current TB testing practices.
Our novel product is based on patented methods for which we obtained an exclusive University of Minnesota patent option: Mycobacterium Biomarkers and Methods, Patent No.: US 10,324,090 Jun. 18, 2019; Option approved August 17, 2022, with an exclusive license agreement achieved July 24, 2025. We seek to validate the claims of this patent and to broaden the base of our patent portfolio through additional proprietary concepts.
Our Team
Thomas Dow, MD | CEO & Co-Founder
Srinand Sreevatsan, PhD | Acting Chief Science Officer
John Haaland, PhD | Founding Director
Physician, researcher, and author; international expert on the association between MAP and human disease; a leader in communicating our TB Rapid Testing features; award-winner at the Minnesota Walleye Tank pitch competition Winter 2023.
John Haaland, PhD | Founding Director
Srinand Sreevatsan, PhD | Acting Chief Science Officer
John Haaland, PhD | Founding Director
Seasoned biotechnology executive with proven experience in large companies including Honeywell and Pillsbury. Created the first food safety system to implement HACCP. CEO of an early-stage biotech startup, Discovery Genomics, before starting MAP/PATH in 2018.
Srinand Sreevatsan, PhD | Acting Chief Science Officer
Srinand Sreevatsan, PhD | Acting Chief Science Officer
Srinand Sreevatsan, PhD | Acting Chief Science Officer
Dean of the College of Veterinary Medicine, University of Missouri; global expert on biomarkers in human and animal hosts; focuses on the world greatest infectious diseases including those caused by mycobacteria, prions, and influenza A; inventor of the 2019 University of Minnesota biomarker patent.
Mark Boyle | Senior Advisor
Srinand Sreevatsan, PhD | Acting Chief Science Officer
Srinand Sreevatsan, PhD | Acting Chief Science Officer
Accomplished, results-oriented senior business executive with demonstrated success commercializing in-vitro diagnostic products for global healthcare markets; played critical and key role in the launch and commercialization of the QuantiFERON-TB test, leading global market development with Cellestis and QIAGEN to create a $100 million global business franchise.
Wendy Thanassi, MD | Senior Advisor
Benjamin Hackel, PhD | Researcher & Science Advisor
Benjamin Hackel, PhD | Researcher & Science Advisor
Formerly with Stanford University and now Sr. Medical Director, TB & Infectious Diseases at QIAGEN; with their consent she remains an advisor to MAP/PATH; an internationally recognized expert in tuberculosis screening in workforces and major institutions including the Veteran’s Administration and CDC.
Benjamin Hackel, PhD | Researcher & Science Advisor
Benjamin Hackel, PhD | Researcher & Science Advisor
Benjamin Hackel, PhD | Researcher & Science Advisor
Expert in protein engineering technologies and endolysins; Professor & Director of Graduate Studies in Chemical Engineering, University of Minnesota.
NEWS
MAP/PATH WINS AWARD IN MINNESOTA'S "WALLYEYE TANK" WINTER 2023 COMPETITION
Walleye Tank is Minnesota’s medical and life science pitch competition providing an educational and promotional opportunity for emerging and established medical and life science companies. MAP/PATH LLC was awarded the second place prize in the Winter 2023 competition held in December.
The competition is a collaboration between the Office of Entrepreneurship Mayo Clinic and University of Minnesota Technology Commercialization. Walleye Tank is curated by a diverse audience of investors and subject matter experts who guide entrepreneurs in every business development stage.